New Article information at Drug Development Technology New and updated information from Article listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Article information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C http://www.drugdevelopment-technology.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/ http://www.drugdevelopment-technology.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/ MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6). Tue, 08 Aug 2017 23:00:00 GMT July’s top stories: NCI and COG’s paediatric precision cancer trial, AstraZeneca’s NSCLC trial results http://www.drugdevelopment-technology.com/features/featurejuly-2017-top-news-stories-drug-5887962/ http://www.drugdevelopment-technology.com/features/featurejuly-2017-top-news-stories-drug-5887962/ NIH’s unit NCI and the COG initiated patient enrolment in a paediatric Phase II clinical trial to evaluate targeted cancer medicines, and AstraZeneca reported positive results from the FLAURA trial of Tagrisso to treat patients with locally advanced … Sun, 06 Aug 2017 23:00:00 GMT Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection http://www.drugdevelopment-technology.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/ http://www.drugdevelopment-technology.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/ Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six. Thu, 27 Jul 2017 23:00:00 GMT Tremfya (guselkumab) for the Treatment of Plaque Psoriasis http://www.drugdevelopment-technology.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/ http://www.drugdevelopment-technology.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/ Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis. Tue, 25 Jul 2017 23:00:00 GMT Endari for the Treatment of Sickle Cell Disease http://www.drugdevelopment-technology.com/projects/endari-for-the-treatment-of-sickle-cell-disease/ http://www.drugdevelopment-technology.com/projects/endari-for-the-treatment-of-sickle-cell-disease/ Endari™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease. Sun, 23 Jul 2017 23:00:00 GMT Haegarda for the Preventive Treatment of Hereditary Angioedema http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients. Wed, 12 Jul 2017 23:00:00 GMT Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC). Thu, 06 Jul 2017 23:00:00 GMT Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Lig… Thu, 06 Jul 2017 23:00:00 GMT June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial http://www.drugdevelopment-technology.com/features/featurejunes-top-stories-nihs-phase-iii-trial-for-chikungunya-boehringer-and-lillys-empagliflozin-trial-5859422/ http://www.drugdevelopment-technology.com/features/featurejunes-top-stories-nihs-phase-iii-trial-for-chikungunya-boehringer-and-lillys-empagliflozin-trial-5859422/ A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k… Tue, 04 Jul 2017 23:00:00 GMT Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above. Thu, 29 Jun 2017 23:00:00 GMT Truxima (rituximab) for the Treatment of Cancer http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… Thu, 08 Jun 2017 23:00:00 GMT Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA). Sun, 04 Jun 2017 23:00:00 GMT May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II http://www.drugdevelopment-technology.com/features/featuremays-top-stories-funders-ngos-agree-on-new-trial-standards-actinogens-xanamem-in-phase-ii-5825756/ http://www.drugdevelopment-technology.com/features/featuremays-top-stories-funders-ngos-agree-on-new-trial-standards-actinogens-xanamem-in-phase-ii-5825756/ Medical research funders and international NGOs agreed to implement the new WHO standards for clinical trials, and Actinogen Medical began patient enrolment and dosing in the Phase II XanADu clinical trial of Xanamem for the treatment of Alzheimer’s … Sun, 04 Jun 2017 23:00:00 GMT Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1. Wed, 31 May 2017 23:00:00 GMT Dinutuximab beta for the Treatment of Neuroblastoma http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. Thu, 18 May 2017 23:00:00 GMT Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Tue, 16 May 2017 23:00:00 GMT Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS). Sun, 14 May 2017 23:00:00 GMT Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC). Sun, 07 May 2017 23:00:00 GMT Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytos… Tue, 02 May 2017 23:00:00 GMT April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ http://www.drugdevelopment-technology.com/features/featureaprils-top-stories-niaids-phase-iiiib-zika-vaccine-trial-boehringers-nintedanib-in-phase-iii-5800076/ The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of ninteda… Tue, 02 May 2017 23:00:00 GMT